Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-Marketing Surveillance to Evaluate the Safety and Effectiveness of Risankizumab (Skyrizi) in Adult Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis Patients

NCT04433442 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04433442
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04433442 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-Marketing Surveillance to Evaluate the Safety and Effectiveness of Risankizumab (Skyrizi) in Adult Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis Patients
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
August 4, 2020
Completion date
June 13, 2025
Enrollment
2,324 (actual)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis, psoriatic arthritis